Entropy Neurodynamics

Entropy Neurodynamics Accounts Payable

The Accounts Payable of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 216,613.00 AUD. In the previous year, Accounts Payable was 220,588.00 AUD — a change of -1.80% (lower).

Accounts Payable

216,613.00AUD

YoY

-1.80%

Last updated:

Accounts Payable of Entropy Neurodynamics is 2026 216,613.00 AUD. Accounts Payable of Entropy Neurodynamics was 2025 220,588.00 AUD. It decreases by -1.80% lower compared to the previous year.

The Entropy Neurodynamics Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
36,527.00 AUD
Jan 1, 2020
137,615.00 AUD
Jan 1, 2021
306,434.00 AUD
Jan 1, 2022
214,460.00 AUD
Jan 1, 2023
38,870.00 AUD
Jan 1, 2024
1.27 M AUD
Jan 1, 2025
220,588.00 AUD
Jan 1, 2026
216,613.00 AUD
The Entropy Neurodynamics Accounts Payable history
YEARAccounts PayableYoY
216,613.00AUD-1.80%
220,588.00AUD-82.62%
1.27 MAUD+3,165.11%
38,870.00AUD-81.88%
214,460.00AUD-30.01%
306,434.00AUD+122.67%
137,615.00AUD+276.75%
36,527.00AUD-42.43%
63,451.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Accounts Payable of Entropy Neurodynamics is 216,613.00 AUD in 2026.

Accounts Payable of Entropy Neurodynamics changed from 220,588.00 AUD to 216,613.00 AUD, representing a -1.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics